Journal of Endocrinology

References

1. ↵
   1. Agarwal AK &
   2. Garg A

   2004 Seipin: a mysterious protein. Trends in Molecular Medicine 10 440–444doi:10.1016/j.molmed.2004.07.009.
2. ↵
   1. Agarwal AK,
   2. Arioglu E,
   3. De Almeida S,
   4. Akkoc N,
   5. Taylor SI,
   6. Bowcock AM,
   7. Barnes RI &
   8. Garg A

   2002 AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nature Genetics 31 21–23doi:10.1038/ng880.
3. ↵
   1. Agarwal AK,
   2. Fryns JP,
   3. Auchus RJ &
   4. Garg A

   2003 Zinc metalloproteinase, ZMPSTE24, is mutated in mandibuloacral dysplasia. Human Molecular Genetics 12 1995–2001doi:10.1093/hmg/ddg213.
4. ↵
   1. Agostini M,
   2. Schoenmakers E,
   3. Mitchell C,
   4. Szatmari I,
   5. Savage D,
   6. Smith A,
   7. Rajanayagam O,
   8. Semple R,
   9. Luan J,
   10. Bath L
   11. et al.

   2006 Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance. Cell Metabolism 4 303–311doi:10.1016/j.cmet.2006.09.003.
5. ↵
   1. Antuna-Puente B,
   2. Boutet E,
   3. Vigouroux C,
   4. Lascols O,
   5. Slama L,
   6. Caron-Debarle M,
   7. Khallouf E,
   8. Lévy-Marchal C,
   9. Capeau J,
   10. Bastard JP &
   11. Magré J

   2010 Higher adiponectin levels in patients with Berardinelli-Seip congenital lipodystrophy due to seipin as compared with 1-acylglycerol-3-phosphate-o-acyltransferase-2 deficiency. Journal of Clinical Endocrinology and Metabolism 95 1463–1468doi:10.1210/jc.2009-1824.
6. ↵
   1. Bluher M

   2009 The distinction of metabolically ‘healthy’ from ‘unhealthy’ obese individuals. Current Opinion in Lipidology 21 38–43doi:10.1097/MOL.0b013e3283346ccc.
7. ↵
   1. Boguslavsky RL,
   2. Stewart CL &
   3. Worman HJ

   2006 Nuclear lamin A inhibits adipocyte differentiation: implications for Dunnigan-type familial partial lipodystrophy. Human Molecular Genetics 15 653–663doi:10.1093/hmg/ddi480.
8. ↵
   1. Boutet E,
   2. El Mourabit H,
   3. Prot M,
   4. Nemani M,
   5. Khallouf E,
   6. Colard O,
   7. Maurice M,
   8. Durand-Schneider AM,
   9. Chretien Y,
   10. Gres S
   11. et al.

   2009 Seipin deficiency alters fatty acid Delta9 desaturation and lipid droplet formation in Berardinelli–Seip congenital lipodystrophy. Biochimie 91 796–803doi:10.1016/j.biochi.2009.01.011.
9. ↵
   1. Cao H &
   2. Hegele RA

   2000 Nuclear lamin A/C R482Q mutation in canadian kindreds with Dunnigan-type familial partial lipodystrophy. Human Molecular Genetics 9 109–112doi:10.1093/hmg/9.1.109.
10. ↵
    1. Cao H,
    2. Alston L,
    3. Ruschman J &
    4. Hegele RA

    2008 Heterozygous CAV1 frameshift mutations (MIM 601047) in patients with atypical partial lipodystrophy and hypertriglyceridemia. Lipids in Health and Disease 7 3doi:10.1186/1476-511X-7-3.
11. ↵
    1. Capanni C,
    2. Cenni V,
    3. Mattioli E,
    4. Sabatelli P,
    5. Ognibene A,
    6. Columbaro M,
    7. Parnaik VK,
    8. Wehnert M,
    9. Maraldi NM,
    10. Squarzoni S
    11. et al.

    2003 Failure of lamin A/C to functionally assemble in R482L mutated familial partial lipodystrophy fibroblasts: altered intermolecular interaction with emerin and implications for gene transcription. Experimental Cell Research 291 122–134doi:10.1016/S0014-4827(03)00395-1.
12. ↵
    1. Capanni C,
    2. Mattioli E,
    3. Columbaro M,
    4. Lucarelli E,
    5. Parnaik VK,
    6. Novelli G,
    7. Wehnert M,
    8. Cenni V,
    9. Maraldi NM,
    10. Squarzoni S
    11. et al.

    2005 Altered pre-lamin A processing is a common mechanism leading to lipodystrophy. Human Molecular Genetics 14 1489–1502doi:10.1093/hmg/ddi158.
13. ↵
    1. Chong AY,
    2. Lupsa BC,
    3. Cochran EK &
    4. Gorden P

    2009 Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia 53 27–35doi:10.1007/s00125-009-1502-9.
14. ↵
    1. Cohen AW,
    2. Combs TP,
    3. Scherer PE &
    4. Lisanti MP

    2003 Role of caveolin and caveolae in insulin signaling and diabetes. American Journal of Physiology. Endocrinology and Metabolism 285 E1151–E1160doi:10.1152/ajpendo.00324.2003.
15. ↵
    1. Colombo C,
    2. Cutson JJ,
    3. Yamauchi T,
    4. Vinson C,
    5. Kadowaki T,
    6. Gavrilova O &
    7. Reitman ML

    2002 Transplantation of adipose tissue lacking leptin is unable to reverse the metabolic abnormalities associated with lipoatrophy. Diabetes 51 2727–2733doi:10.2337/diabetes.51.9.2727.
16. ↵
    1. Danforth E Jr.

    2000 Failure of adipocyte differentiation causes type II diabetes mellitus? Nature Genetics 26 13doi:10.1038/79111.
17. ↵
    1. Dechat T,
    2. Pfleghaar K,
    3. Sengupta K,
    4. Shimi T,
    5. Shumaker DK,
    6. Solimando L &
    7. Goldman RD

    2008 Nuclear lamins: major factors in the structural organization and function of the nucleus and chromatin. Genes and Development 22 832–853doi:10.1101/gad.1652708.
18. ↵
    1. DeFronzo RA

    2010 Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 53 1270–1287doi:10.1007/s00125-010-1684-1.
19. ↵
    1. Desvergne B &
    2. Wahli W

    1999 Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocrine Reviews 20 649–688doi:10.1210/er.20.5.649.
20. ↵
    1. Dib K,
    2. Whitehead JP,
    3. Humphreys PJ,
    4. Soos MA,
    5. Baynes KC,
    6. Kumar S,
    7. Harvey T &
    8. O'Rahilly S

    1998 Impaired activation of phosphoinositide 3-kinase by insulin in fibroblasts from patients with severe insulin resistance and pseudoacromegaly. A disorder characterized by selective postreceptor insulin resistance. Journal of Clinical Investigation 101 1111–1120doi:10.1172/JCI119884.
21. ↵
    1. Donnelly KL,
    2. Smith CI,
    3. Schwarzenberg SJ,
    4. Jessurun J,
    5. Boldt MD &
    6. Parks EJ

    2005 Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. Journal of Clinical Investigation 115 1343–1351doi:10.1172/JCI23621.
22. ↵
    1. Erion DM &
    2. Shulman GI

    2010 Diacylglycerol-mediated insulin resistance. Nature Medicine 16 400–402doi:10.1038/nm0410-400.
23. ↵
    1. Fei W,
    2. Shui G,
    3. Gaeta B,
    4. Du X,
    5. Kuerschner L,
    6. Li P,
    7. Brown AJ,
    8. Wenk MR,
    9. Parton RG &
    10. Yang H

    2008 Fld1p, a functional homologue of human seipin, regulates the size of lipid droplets in yeast. Journal of Cell Biology 180 473–482doi:10.1083/jcb.200711136.
24. ↵
    1. de Ferranti S &
    2. Mozaffarian D

    2008 The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences. Clinical Chemistry 54 945–955doi:10.1373/clinchem.2007.100156.
25. ↵
    1. Flier JS,
    2. Moller DE,
    3. Moses AC,
    4. O'Rahilly S,
    5. Chaiken RL,
    6. Grigorescu F,
    7. Elahi D,
    8. Kahn BB,
    9. Weinreb JE &
    10. Eastman R

    1993 Insulin-mediated pseudoacromegaly: clinical and biochemical characterization of a syndrome of selective insulin resistance. Journal of Clinical Endocrinology and Metabolism 76 1533–1541doi:10.1210/jc.76.6.1533.
26. ↵
    1. Frayn KN

    2002 Adipose tissue as a buffer for daily lipid flux. Diabetologia 45 1201–1210doi:10.1007/s00125-002-0873-y.
27. ↵
    1. Gale SE,
    2. Frolov A,
    3. Han X,
    4. Bickel PE,
    5. Cao L,
    6. Bowcock A,
    7. Schaffer JE &
    8. Ory DS

    2006 A regulatory role for 1-acylglycerol-3-phosphate-O-acyltransferase 2 in adipocyte differentiation. Journal of Biological Chemistry 281 11082–11089doi:10.1074/jbc.M509612200.
28. ↵
    1. Garg A

    2004 Acquired and inherited lipodystrophies. New England Journal of Medicine 350 1220–1234doi:10.1056/NEJMra025261.
29. ↵
    1. Garg A,
    2. Fleckenstein JL,
    3. Peshock RM &
    4. Grundy SM

    1992 Peculiar distribution of adipose tissue in patients with congenital generalized lipodystrophy. Journal of Clinical Endocrinology and Metabolism 75 358–361doi:10.1210/jc.75.2.358.
30. ↵
    1. Garg A,
    2. Peshock RM &
    3. Fleckenstein JL

    1999 Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety). Journal of Clinical Endocrinology and Metabolism 84 170–174doi:10.1210/jc.84.1.170.
31. ↵
    1. Gavrilova O,
    2. Marcus-Samuels B,
    3. Graham D,
    4. Kim JK,
    5. Shulman GI,
    6. Castle AL,
    7. Vinson C,
    8. Eckhaus M &
    9. Reitman ML

    2000 Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. Journal of Clinical Investigation 105 271–278doi:10.1172/JCI7901.
32. ↵
    1. George S,
    2. Rochford JJ,
    3. Wolfrum C,
    4. Gray SL,
    5. Schinner S,
    6. Wilson JC,
    7. Soos MA,
    8. Murgatroyd PR,
    9. Williams RM,
    10. Acerini CL
    11. et al.

    2004 A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science 304 1325–1328doi:10.1126/science.1096706.
33. ↵
    1. Gesta S,
    2. Bluher M,
    3. Yamamoto Y,
    4. Norris AW,
    5. Berndt J,
    6. Kralisch S,
    7. Boucher J,
    8. Lewis C &
    9. Kahn CR

    2006 Evidence for a role of developmental genes in the origin of obesity and body fat distribution. PNAS 103 6676–6681doi:10.1073/pnas.0601752103.
34. ↵
    1. Gray SL,
    2. Nora ED,
    3. Grosse J,
    4. Manieri M,
    5. Stoeger T,
    6. Medina-Gomez G,
    7. Burling K,
    8. Wattler S,
    9. Russ A,
    10. Yeo GS
    11. et al.

    2006 Leptin deficiency unmasks the deleterious effects of impaired peroxisome proliferator-activated receptor gamma function (P465L PPARgamma) in mice. Diabetes 55 2669–2677doi:10.2337/db06-0389.
35. ↵
    1. Haque W,
    2. Garg A &
    3. Agarwal AK

    2005 Enzymatic activity of naturally occurring 1-acylglycerol-3-phosphate-O-acyltransferase 2 mutants associated with congenital generalized lipodystrophy. Biochemical and Biophysical Research Communications 327 446–453doi:10.1016/j.bbrc.2004.12.024.
36. ↵
    1. Hayashi YK,
    2. Matsuda C,
    3. Ogawa M,
    4. Goto K,
    5. Tominaga K,
    6. Mitsuhashi S,
    7. Park YE,
    8. Nonaka I,
    9. Hino-Fukuyo N,
    10. Haginoya K
    11. et al.

    2009 Human PTRF mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy. Journal of Clinical Investigation 119 2623–2633doi:10.1172/JCI38660.
37. ↵
    1. Hill MM,
    2. Bastiani M,
    3. Luetterforst R,
    4. Kirkham M,
    5. Kirkham A,
    6. Nixon SJ,
    7. Walser P,
    8. Abankwa D,
    9. Oorschot VM,
    10. Martin S
    11. et al.

    2008 PTRF-Cavin, a conserved cytoplasmic protein required for caveola formation and function. Cell 132 113–124doi:10.1016/j.cell.2007.11.042.
38. ↵
    1. Kershaw EE &
    2. Flier JS

    2004 Adipose tissue as an endocrine organ. Journal of Clinical Endocrinology and Metabolism 89 2548–2556doi:10.1210/jc.2004-0395.
39. ↵
    1. Kim JB &
    2. Spiegelman BM

    1996 ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Genes and Development 10 1096–1107doi:10.1101/gad.10.9.1096.
40. ↵
    1. Kim JK,
    2. Fillmore JJ,
    3. Gavrilova O,
    4. Chao L,
    5. Higashimori T,
    6. Choi H,
    7. Kim HJ,
    8. Yu C,
    9. Chen Y,
    10. Qu X
    11. et al.

    2003 Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice. Diabetes 52 1311–1318doi:10.2337/diabetes.52.6.1311.
41. ↵
    1. Kim JY,
    2. van de Wall E,
    3. Laplante M,
    4. Azzara A,
    5. Trujillo ME,
    6. Hofmann SM,
    7. Schraw T,
    8. Durand JL,
    9. Li H,
    10. Li G
    11. et al.

    2007 Obesity-associated improvements in metabolic profile through expansion of adipose tissue. Journal of Clinical Investigation 117 2621–2637doi:10.1172/JCI31021.
42. ↵
    1. Kim CA,
    2. Delepine M,
    3. Boutet E,
    4. El Mourabit H,
    5. Le Lay S,
    6. Meier M,
    7. Nemani M,
    8. Bridel E,
    9. Leite CC,
    10. Bertola DR
    11. et al.

    2008 Association of a homozygous nonsense caveolin-1 mutation with Berardinelli–Seip congenital lipodystrophy. Journal of Clinical Endocrinology and Metabolism 93 1129–1134doi:10.1210/jc.2007-1328.
43. ↵
    1. Koutkia P,
    2. Schurgin S,
    3. Berry J,
    4. Breu J,
    5. Lee BS,
    6. Klibanski A &
    7. Grinspoon S

    2005 Reciprocal changes in endogenous ghrelin and growth hormone during fasting in healthy women. American Journal of Physiology. Endocrinology and Metabolism 289 E814–E822doi:10.1152/ajpendo.00093.2005.
44. ↵
    1. Lane MD &
    2. Tang QQ

    2005 From multipotent stem cell to adipocyte. Birth Defects Research. Part A, Clinical and Molecular Teratology 73 476–477doi:10.1002/bdra.20150.
45. ↵
    1. Liu L &
    2. Pilch PF

    2008 A critical role of cavin (polymerase I and transcript release factor) in caveolae formation and organization. Journal of Biological Chemistry 283 4314–4322doi:10.1074/jbc.M707890200.
46. ↵
    1. Liu L,
    2. Brown D,
    3. McKee M,
    4. Lebrasseur NK,
    5. Yang D,
    6. Albrecht KH,
    7. Ravid K &
    8. Pilch PF

    2008 Deletion of Cavin/PTRF causes global loss of caveolae, dyslipidemia, and glucose intolerance. Cell Metabolism 8 310–317doi:10.1016/j.cmet.2008.07.008.
47. ↵
    1. Lloyd DJ,
    2. Trembath RC &
    3. Shackleton S

    2002 A novel interaction between lamin A and SREBP1: implications for partial lipodystrophy and other laminopathies. Human Molecular Genetics 11 769–777doi:10.1093/hmg/11.7.769.
48. ↵
    1. Magre J,
    2. Delepine M,
    3. Khallouf E,
    4. Gedde-Dahl T Jr.,
    5. Van Maldergem L,
    6. Sobel E,
    7. Papp J,
    8. Meier M,
    9. Megarbane A,
    10. Bachy A
    11. et al.

    2001 Identification of the gene altered in Berardinelli–Seip congenital lipodystrophy on chromosome 11q13. Nature Genetics 28 365–370doi:10.1038/ng585.
49. ↵
    1. Misra A &
    2. Garg A

    2003 Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature. Medicine 82 129–146doi:10.1097/00005792-200303000-00007.
50. ↵
    1. Misra A,
    2. Peethambaram A &
    3. Garg A

    2004 Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. Medicine 83 18–34doi:10.1097/01.md.0000111061.69212.59.
51. ↵
    1. Moitra J,
    2. Mason MM,
    3. Olive M,
    4. Krylov D,
    5. Gavrilova O,
    6. Marcus-Samuels B,
    7. Feigenbaum L,
    8. Lee E,
    9. Aoyama T,
    10. Eckhaus M
    11. et al.

    1998 Life without white fat: a transgenic mouse. Genes and Development 12 3168–3181doi:10.1101/gad.12.20.3168.
52. ↵
    1. Nishino N,
    2. Tamori Y,
    3. Tateya S,
    4. Kawaguchi T,
    5. Shibakusa T,
    6. Mizunoya W,
    7. Inoue K,
    8. Kitazawa R,
    9. Kitazawa S,
    10. Matsuki Y
    11. et al.

    2008 FSP27 contributes to efficient energy storage in murine white adipocytes by promoting the formation of unilocular lipid droplets. Journal of Clinical Investigation 118 2808–2821doi:10.1172/JCI34090.
53. ↵
    1. Payne VA,
    2. Grimsey N,
    3. Tuthill A,
    4. Virtue S,
    5. Gray SL,
    6. Dalla Nora E,
    7. Semple RK,
    8. O'Rahilly S &
    9. Rochford JJ

    2008 The human lipodystrophy gene BSCL2/seipin may be essential for normal adipocyte differentiation. Diabetes 57 2055–2060doi:10.2337/db08-0184.
54. ↵
    1. Petersen KF,
    2. Dufour S,
    3. Savage DB,
    4. Bilz S,
    5. Solomon G,
    6. Yonemitsu S,
    7. Cline GW,
    8. Befroy D,
    9. Zemany L,
    10. Kahn BB
    11. et al.

    2007 The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. PNAS 104 12587–12594doi:10.1073/pnas.0705408104.
55. ↵
    1. Poitout V &
    2. Robertson RP

    2008 Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocrine Reviews 29 351–366doi:10.1210/er.2007-0023.
56. ↵
    1. Puri V,
    2. Konda S,
    3. Ranjit S,
    4. Aouadi M,
    5. Chawla A,
    6. Chouinard M,
    7. Chakladar A &
    8. Czech MP

    2007 Fat-specific protein 27, a novel lipid droplet protein that enhances triglyceride storage. Journal of Biological Chemistry 282 34213–34218doi:10.1074/jbc.M707404200.
57. ↵
    1. Robbins DC,
    2. Danforth E Jr.,
    3. Horton ES,
    4. Burse RL,
    5. Goldman RF &
    6. Sims EA

    1979 The effect of diet on thermogenesis in acquired lipodystrophy. Metabolism 28 908–916doi:10.1016/0026-0495(79)90090-8.
58. ↵
    1. Rosen ED,
    2. Walkey CJ,
    3. Puigserver P &
    4. Spiegelman BM

    2000 Transcriptional regulation of adipogenesis. Genes and Development 14 1293–1307doi:10.1101/gad.14.11.1293.
59. ↵
    1. Rubio-Cabezas O,
    2. Puri V,
    3. Murano I,
    4. Saudek V,
    5. Semple RK,
    6. Dash S,
    7. Hyden CS,
    8. Bottomley W,
    9. Vigouroux C,
    10. Magre J
    11. et al.

    2009 Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC. EMBO Molecular Medicine 1 280–287doi:10.1002/emmm.200900037.
60. ↵
    1. Saltiel AR &
    2. Kahn CR

    2001 Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414 799–806doi:10.1038/414799a.
61. ↵
    1. Saltiel AR &
    2. Pessin JE

    2003 Insulin signaling in microdomains of the plasma membrane. Traffic 4 711–716doi:10.1034/j.1600-0854.2003.00119.x.
62. ↵
    1. Samuel VT,
    2. Petersen KF &
    3. Shulman GI

    2010 Lipid-induced insulin resistance: unravelling the mechanism. Lancet 375 2267–2277doi:10.1016/S0140-6736(10)60408-4.
63. ↵
    1. Savage DB,
    2. Tan GD,
    3. Acerini CL,
    4. Jebb SA,
    5. Agostini M,
    6. Gurnell M,
    7. Williams RL,
    8. Umpleby AM,
    9. Thomas EL,
    10. Bell JD
    11. et al.

    2003 Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes 52 910–917doi:10.2337/diabetes.52.4.910.
64. ↵
    1. Savage DB,
    2. Petersen KF &
    3. Shulman GI

    2007a Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiological Reviews 87 507–520doi:10.1152/physrev.00024.2006.
65. ↵
    1. Savage DB,
    2. Semple RK,
    3. Chatterjee VK,
    4. Wales JK,
    5. Ross RJ &
    6. O'Rahilly S

    2007b A clinical approach to severe insulin resistance. Endocrine Development 11 122–132doi:10.1159/000111067.
66. ↵
    1. Savage DB,
    2. Semple RK,
    3. Clatworthy MR,
    4. Lyons PA,
    5. Morgan BP,
    6. Cochran EK,
    7. Gorden P,
    8. Raymond-Barker P,
    9. Murgatroyd PR,
    10. Adams C
    11. et al.

    2009 Complement abnormalities in acquired lipodystrophy revisited. Journal of Clinical Endocrinology and Metabolism 94 10–16doi:10.1210/jc.2008-1703.
67. ↵
    1. Schlegel A,
    2. Volonte D,
    3. Engelman JA,
    4. Galbiati F,
    5. Mehta P,
    6. Zhang XL,
    7. Scherer PE &
    8. Lisanti MP

    1998 Crowded little caves: structure and function of caveolae. Cellular Signalling 10 457–463doi:10.1016/S0898-6568(98)00007-2.
68. ↵
    1. Seip M &
    2. Trygstad O

    1996 Generalized lipodystrophy, congenital and acquired (lipoatrophy). Acta Paediatric. Supplementum 413 2–28doi:10.1111/j.1651-2227.1996.tb14262.x.
69. ↵
    1. Semple RK,
    2. Soos MA,
    3. Luan J,
    4. Mitchell CS,
    5. Wilson JC,
    6. Gurnell M,
    7. Cochran EK,
    8. Gorden P,
    9. Chatterjee VK,
    10. Wareham NJ
    11. et al.

    2006 Elevated plasma adiponectin in humans with genetically defective insulin receptors. Journal of Clinical Endocrinology and Metabolism 91 3219–3223doi:10.1210/jc.2006-0166.
70. ↵
    1. Semple RK,
    2. Halberg NH,
    3. Burling K,
    4. Soos MA,
    5. Schraw T,
    6. Luan J,
    7. Cochran EK,
    8. Dunger DB,
    9. Wareham NJ,
    10. Scherer PE
    11. et al.

    2007 Paradoxical elevation of high-molecular weight adiponectin in acquired extreme insulin resistance due to insulin receptor antibodies. Diabetes 56 1712–1717doi:10.2337/db06-1665.
71. ↵
    1. Semple RK,
    2. Cochran EK,
    3. Soos MA,
    4. Burling KA,
    5. Savage DB,
    6. Gorden P &
    7. O'Rahilly S

    2008 Plasma adiponectin as a marker of insulin receptor dysfunction: clinical utility in severe insulin resistance. Diabetes Care 31 977–979doi:10.2337/dc07-2194.
72. ↵
    1. Semple RK,
    2. Sleigh A,
    3. Murgatroyd PR,
    4. Adams CA,
    5. Bluck L,
    6. Jackson S,
    7. Vottero A,
    8. Kanabar D,
    9. Charlton-Menys V,
    10. Durrington P
    11. et al.

    2009 Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. Journal of Clinical Investigation 119 315–322doi:10.1172/JCI37432.
73. ↵
    1. Weiss RE &
    2. Refetoff S

    1. Semple RK,
    2. Savage DB,
    3. Halsall DJ &
    4. O'Rahilly S

    2010 Syndromes of severe insulin resistance and/or lipodystrophy. In Genetic Diagnosis of Endocrine Disorders, Eds Weiss RE & Refetoff S. London: Elsevier.
74. ↵
    1. Sennello JA,
    2. Fayad R,
    3. Pini M,
    4. Gove ME &
    5. Fantuzzi G

    2006 Transplantation of wild-type white adipose tissue normalizes metabolic, immune and inflammatory alterations in leptin-deficient ob/ob mice. Cytokine 36 261–266doi:10.1016/j.cyto.2007.02.001.
75. ↵
    1. Shackleton S,
    2. Lloyd DJ,
    3. Jackson SN,
    4. Evans R,
    5. Niermeijer MF,
    6. Singh BM,
    7. Schmidt H,
    8. Brabant G,
    9. Kumar S,
    10. Durrington PN
    11. et al.

    2000 LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nature Genetics 24 153–156doi:10.1038/72807.
76. ↵
    1. Simha V &
    2. Garg A

    2003 Phenotypic heterogeneity in body fat distribution in patients with congenital generalized lipodystrophy caused by mutations in the AGPAT2 or seipin genes. Journal of Clinical Endocrinology and Metabolism 88 5433–5437doi:10.1210/jc.2003-030835.
77. ↵
    1. Sissons JG,
    2. West RJ,
    3. Fallows J,
    4. Williams DG,
    5. Boucher BJ,
    6. Amos N &
    7. Peters DK

    1976 The complement abnormalities of lipodystrophy. New England Journal of Medicine 294 461–465doi:10.1056/NEJM197602262940902.
78. ↵
    1. Snijder MB,
    2. Zimmet PZ,
    3. Visser M,
    4. Dekker JM,
    5. Seidell JC &
    6. Shaw JE

    2004 Independent and opposite associations of waist and hip circumferences with diabetes, hypertension and dyslipidemia: the AusDiab Study. International Journal of Obesity and Related Metabolic Disorders 28 402–409doi:10.1038/sj.ijo.0802567.
79. ↵
    1. Spalding KL,
    2. Arner E,
    3. Westermark PO,
    4. Bernard S,
    5. Buchholz BA,
    6. Bergmann O,
    7. Blomqvist L,
    8. Hoffstedt J,
    9. Naslund E,
    10. Britton T
    11. et al.

    2008 Dynamics of fat cell turnover in humans. Nature 453 783–787doi:10.1038/nature06902.
80. ↵
    1. Speckman RA,
    2. Garg A,
    3. Du F,
    4. Bennett L,
    5. Veile R,
    6. Arioglu E,
    7. Taylor SI,
    8. Lovett M &
    9. Bowcock AM

    2000 Mutational and haplotype analyses of families with familial partial lipodystrophy (Dunnigan variety) reveal recurrent missense mutations in the globular C-terminal domain of lamin A/C. American Journal of Human Genetics 66 1192–1198doi:10.1086/302836.
81. ↵
    1. Spiegelman BM

    1998 PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47 507–514doi:10.2337/diabetes.47.4.507.
82. ↵
    1. Szymanski KM,
    2. Binns D,
    3. Bartz R,
    4. Grishin NV,
    5. Li WP,
    6. Agarwal AK,
    7. Garg A,
    8. Anderson RG &
    9. Goodman JM

    2007 The lipodystrophy protein seipin is found at endoplasmic reticulum lipid droplet junctions and is important for droplet morphology. PNAS 104 20890–20895doi:10.1073/pnas.0704154104.
83. ↵
    1. Tan GD,
    2. Savage DB,
    3. Fielding BA,
    4. Collins J,
    5. Hodson L,
    6. Humphreys SM,
    7. O'Rahilly S,
    8. Chatterjee K,
    9. Frayn KN &
    10. Karpe F

    2008 Fatty acid metabolism in patients with PPARgamma mutations. Journal of Clinical Endocrinology and Metabolism 93 4462–4470doi:10.1210/jc.2007-2356.
84. ↵
    1. Tershakovec AM,
    2. Frank I &
    3. Rader D

    2004 HIV-related lipodystrophy and related factors. Atherosclerosis 174 1–10doi:10.1016/S0021-9150(03)00246-6.
85. ↵
    1. Tran TT,
    2. Yamamoto Y,
    3. Gesta S &
    4. Kahn CR

    2008 Beneficial effects of subcutaneous fat transplantation on metabolism. Cell Metabolism 7 410–420doi:10.1016/j.cmet.2008.04.004.
86. ↵
    1. Virtue S &
    2. Vidal-Puig A

    2008 It's not how fat you are, it's what you do with it that counts. PLoS Biology 6 e237doi:10.1371/journal.pbio.0060237.
87. ↵
    1. Williams DG

    1997 C3 nephritic factor and mesangiocapillary glomerulonephritis. Pediatric Nephrology 11 96–98doi:10.1007/s004670050241.
88. ↵
    1. Wojtanik KM,
    2. Edgemon K,
    3. Viswanadha S,
    4. Lindsey B,
    5. Haluzik M,
    6. Chen W,
    7. Poy G,
    8. Reitman M &
    9. Londos C

    2009 The role of LMNA in adipose: a novel mouse model of lipodystrophy based on the Dunnigan-type familial partial lipodystrophy mutation. Journal of Lipid Research 50 1068–1079doi:10.1194/jlr.M800491-JLR200.
89. ↵
    1. Worman HJ &
    2. Bonne G

    2007 "Laminopathies": a wide spectrum of human diseases. Experimental Cell Research 313 2121–2133doi:10.1016/j.yexcr.2007.03.028.